HR-LC-MS based analysis of two antibacterial metabolites from a marine sponge symbiont Streptomyces pharmamarensis ICN40

Joseph, Francis-Joseph Rosemary Sharmila; Iniyan, Appadurai Muthamil; Vincent, Samuel Gnana Prakash

doi:10.1016/j.micpath.2017.09.033

Cited by 10 publications

(9 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Studies have described MIC values >100 μg/mL in crude extracts from Streptomyces strains 86 , while our crude extract from S . fildesensis So13.3 showed a MIC value of 15.6 μg/mL for Gram-positive pathogens (Table 2), which is comparable with reported purified compounds ‒MIC values ranging from 2 to 75 μg/mL 55,87–89 ‒ and with MIC value obtained from nalidixic acid positive control ranging from 2 to 8 μg/mL for susceptible strains ( E . coli ATCC 22925 and Klebsiella pneumoniae ATCC 13883, respectively).…”

Section: Discussionsupporting

confidence: 82%

“…aureus ATCC 25923 and MRSA pathogenic strains. Coincidently, similar analyses with different Streptomyces strains have shown active compounds with R f, ranging from 0.11 to 0.86, where the upper organic phase corresponded to antimicrobial molecules, such as streptoclorine, nigericin and piericidin A1 53–55 . In addition, the result of the LC-ESI-MS/MS revealed an approximation of the molecular weight of the antibiotics produced by Streptomyces fildesensis So13.3.…”

Section: Resultsmentioning

confidence: 65%

See 1 more Smart Citation

Antarctic Streptomyces fildesensis So13.3 strain as a promising source for antimicrobials discovery

Núñez-Montero

Lamilla

Abanto

et al. 2019

Sci Rep

View full text Add to dashboard Cite

Antarctic have been suggested as an attractive source for antibiotics discovery and members of Streptomyces genus have historically been studied as natural producers of antimicrobial metabolites. Nonetheless, our knowledge on antibiotic-producing Streptomyces from Antarctic is very limited. In this study, the antimicrobial activity of organic extracts from Antarctic Streptomyces strains was evaluated by disk diffusion assays and minimum inhibitory concentration. The strain Streptomyces sp. So13.3 showed the greatest antibiotic activity (MIC = 15.6 μg/mL) against Gram-positive bacteria and growth reduction of Gram‒negative pathogens. The bioactive fraction in the crude extract was revealed by TLC‒bioautography at R f = 0.78 with molecular weight between 148 and 624 m/z detected by LC-ESI-MS/MS. The strain So13.3 was taxonomically affiliated as Streptomyces fildesensis . Whole genome sequencing and analysis suggested a 9.47 Mb genome size with 42 predicted biosynthetic gene clusters (BGCs) and 56 putative clusters representing a 22% of total genome content. Interestingly, a large number of them (11 of 42 BGCs and 40 of 56 putative BGCs), did not show similarities with other known BGCs. Our results highlight the potential of the Antarctic Streptomyces strains as a promising source of novel antimicrobials, particularly the strain Streptomyces fildesensis So13.3, which first draft genome is reported in this work.

show abstract

Section: Discussionsupporting

confidence: 82%

Section: Resultsmentioning

confidence: 65%

Antarctic Streptomyces fildesensis So13.3 strain as a promising source for antimicrobials discovery

Núñez-Montero

Lamilla

Abanto

et al. 2019

Sci Rep

View full text Add to dashboard Cite

show abstract

“…Compounds PVI401 and PVI402 exhibited antibacterial activity against MRSA, ( Table 3 ), however, only PVI401 showed antibiofilm activity toward S. aureus ATCC25923; this effect was dependent on the concentration obtained in the antibacterial assay of compound PVI401, with poor biofilm formation when compared to controls when the pathogen was treated with a 4× MIC concentration at 2 μg/mL, of PVI401 [ 134 ].…”

Section: Resultsmentioning

confidence: 99%

Marine Actinobacteria a New Source of Antibacterial Metabolites to Treat Acne Vulgaris Disease—A Systematic Literature Review

2022

View full text Add to dashboard Cite

Acne vulgaris is a multifactorial disease that remains under-explored; up to date it is known that the bacterium Cutibacterium acnes is involved in the disease occurrence, also associated with a microbial dysbiosis. Antibiotics have become a mainstay treatment generating the emergence of antibiotic-resistant bacteria. In addition, there are some reported side effects of alternative treatments, which indicate the need to investigate a different therapeutic approach. Natural products continue to be an excellent option, especially those extracted from actinobacteria, which represent a prominent source of metabolites with a wide range of biological activities, particularly the marine actinobacteria, which have been less studied than their terrestrial counterparts. Therefore, this systematic review aimed to identify and evaluate the potential anti-infective activity of metabolites isolated from marine actinobacteria strains against bacteria related to the development of acne vulgaris disease. It was found that there is a variety of compounds with anti-infective activity against Staphylococcus aureus and Staphylococcus epidermidis, bacteria closely related to acne vulgaris development; nevertheless, there is no report of a compound with antibacterial activity or quorum-sensing inhibition toward C. acnes, which is a surprising result. Since two of the most widely used antibiotics for the treatment of acne targeting C. acnes were obtained from actinobacteria of the genus Streptomyces, this demonstrates a great opportunity to pursue further studies in this field, considering the potential of marine actinobacteria to produce new anti-infective compounds.

show abstract

“…Several publications during 2016-2017 reported on several marine extracts or structurally uncharacterized compounds, with potentially novel preclinical and/or clinical pharmacology: In vitro antibacterial and antibiotic potentiating activities of tropical Mauritian marine sponge extracts [12]; a sterol-rich fraction with significant synergistic antiinflammatory activity isolated from the South Korean soft coral Dendronephthya gigantea [13]; two metabolites with anti-methicillin-resistant Staphylococcus aureus activity from an Indian marine sponge Clathria procera associated actinomycete S. pharmamarensis ICN40 with antimicrobial potential "after structure identification and clinical studies" are completed [14]; 49 of 251 bacterial isolates from sediments from several Red Sea harbor and lagoon environments with the potential to produce secondary metabolites with "antimicrobial activity" [15]; antibacterial activity in extracts from the marine bacterium Salinispora arenicola from the Gulf of California, Mexico [16]; activation by cyanobacterium Oscillatoria sp. lipopolysaccharide of rat microglia and murine B cells with concomitant Toll-like receptor 4 signaling in vitro [17,18]; and lipophilic fractions from the Icelandic marine sponge Halichondria sitiens that decrease dendritic cells' pro-inflammatory cytokine release [19].…”

Section: Introductionmentioning

confidence: 99%

Marine Pharmacology in 2016–2017: Marine Compounds with Antibacterial, Antidiabetic, Antifungal, Anti-Inflammatory, Antiprotozoal, Antituberculosis and Antiviral Activities; Affecting the Immune and Nervous Systems, and Other Miscellaneous Mechanisms of Action

et al. 2021

View full text Add to dashboard Cite

The review of the 2016–2017 marine pharmacology literature was prepared in a manner similar as the 10 prior reviews of this series. Preclinical marine pharmacology research during 2016–2017 assessed 313 marine compounds with novel pharmacology reported by a growing number of investigators from 54 countries. The peer-reviewed literature reported antibacterial, antifungal, antiprotozoal, antituberculosis, and antiviral activities for 123 marine natural products, 111 marine compounds with antidiabetic and anti-inflammatory activities as well as affecting the immune and nervous system, while in contrast 79 marine compounds displayed miscellaneous mechanisms of action which upon further investigation may contribute to several pharmacological classes. Therefore, in 2016–2017, the preclinical marine natural product pharmacology pipeline generated both novel pharmacology as well as potentially new lead compounds for the growing clinical marine pharmaceutical pipeline, and thus sustained with its contributions the global research for novel and effective therapeutic strategies for multiple disease categories.

show abstract

HR-LC-MS based analysis of two antibacterial metabolites from a marine sponge symbiont Streptomyces pharmamarensis ICN40

Cited by 10 publications

References 36 publications

Antarctic Streptomyces fildesensis So13.3 strain as a promising source for antimicrobials discovery

Antarctic Streptomyces fildesensis So13.3 strain as a promising source for antimicrobials discovery

Marine Actinobacteria a New Source of Antibacterial Metabolites to Treat Acne Vulgaris Disease—A Systematic Literature Review

Marine Pharmacology in 2016–2017: Marine Compounds with Antibacterial, Antidiabetic, Antifungal, Anti-Inflammatory, Antiprotozoal, Antituberculosis and Antiviral Activities; Affecting the Immune and Nervous Systems, and Other Miscellaneous Mechanisms of Action

Contact Info

Product

Resources

About